Brief: Arch Biopartners' AB569 receives positive opinion from EMA COMP
26/04/2016 13:34
April 26 (Reuters) - Arch Biopartners Inc ACH.V
* Arch biopartners' AB569 receives positive opinion from EMA
COMP for orphan designation for cystic fibrosis
* Plans to submit an investigational new drug application to
FDA for AB569 in second half of 2016
* COMP's positive opinion will be forwarded to EC for final
approval of orphan designation, expected to be completed in next
few weeks
Source text for Eikon: ID:nMKWfPLb1a
Further company coverage: ACH.V
(Bengaluru Newsroom: +1 646 223 8780)
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide